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RSPO3 impairs barrier function of human
vascular endothelial monolayers and
synergizes with pro-inflammatory IL-1
Tom Skaria1, Esther Bachli2 and Gabriele Schoedon1*
Abstract
Background: Endothelial barrier dysfunction characterized by hyperpermeability of the vascular endothelium is a
key factor in the pathogenesis of chronic inflammatory diseases and affects clinical outcomes. In states of chronic
inflammation, mediators secreted by activated immune cells or vascular endothelium may affect the barrier
function and permeability of the vascular endothelium. The matricellular R-spondin family member RSPO3 is
produced by inflammatory-activated human monocytes and vascular endothelial cells, but its effects in the
regulation of vascular endothelial barrier function remains elusive.
Methods: The present study investigates the effects of RSPO3 on the barrier function of adult human primary
macro- and micro- vascular endothelial monolayers. Tight monolayers of primary endothelial cells from human
coronary and pulmonary arteries, and cardiac, brain, and dermal microvascular beds were treated with RSPO3
either alone or in combination with pro-inflammatory mediator IL-1β. Endothelial barrier function was assessed
non-invasively in real-time using Electric Cell-substrate Impedance Sensing.
Results: RSPO3 treatment critically affected barrier function by enhancing the permeability of all vascular endothelial
monolayers investigated. To confer hyperpermeable phenotype in vascular endothelial monolayers, RSPO3
induced inter-endothelial gap formation by disrupting the β-catenin and VE-cadherin alignment at adherens
junctions. RSPO3 synergistically enhanced the barrier impairing properties of the pro-inflammatory mediator IL-1β.
Conclusion: Here, we show that the matricellular protein RSPO3 is a mediator of endothelial hyperpermeability that
can act in synergy with the inflammatory mediator IL-1β. This finding stimulates further studies to delineate the
endothelial barrier impairing properties of RSPO3 and its synergistic interaction with IL-1β in chronic inflammatory
diseases.
Keywords: Endothelial dysfunction, RSPO3, Inflammation, Vascular leakage, IL-1β
Background
The semipermeable endothelial barrier plays an import-
ant role in maintaining vascular homeostasis as the
tightly controlled vascular permeability permits the
macromolecule transport, immune surveillance and fi-
brin barrier deposition at inflamed sites (Weis, 2008).
Hyperpermeability of the endothelial barrier causing vas-
cular leakage of blood components and immune cell
transmigration is a crucial factor in the pathogenesis of
acute and chronic inflammatory diseases, stroke, and
tumor inflammation. Strategies aimed at stabilizing
endothelial barrier homeostasis prevent tissue damage
and have been suggested to improve therapeutic
outcomes in inflammatory diseases (Chava et al., 2012;
Han et al., 2013).
R-spondin (RSPO)-3, a member of the RSPO family of
matricellular signaling proteins involved in vascular
homeostasis (Aoki et al., 2007; Knight & Hankenson,
2014; Scholz et al., 2016) promotes oncogenesis in solid
tumors (Chartier et al., 2016; Marcucci et al., 2016; Picco
et al., 2017) and hematologic malignancies (van Andel
et al., 2017; Wang et al., 2013). RSPO act as enhancers
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of signaling pathways mediated by Wnt ligands (Chartier
et al., 2016; Knight & Hankenson, 2014; van Andel et al.,
2017), the latter consists of 19 secreted lipid modified
proteins with critical roles in regulating cell adhesion
and endothelial barrier function (Lim et al., 2017; Skaria
et al., 2017a). Previous studies showed that the proto-
typic pro-inflammatory mediator IL-1β (Dinarello, 2011)
significantly induces RSPO3 expression in human mac-
rophages (Williams et al., 2009) and vascular endothelial
cells (accession GSE62281, NCBI GEO data repository)
(Skaria et al., 2017a). However, the role of RSPO3 in the
regulation of vascular endothelial barrier function
remains still unclear. Here, we investigated the effect of
RSPO3 on endothelial monolayer barrier function in
real-time using electric cell-substrate impedance sensing
(ECIS). This study shows for the first time that RSPO3
(1) directly and dose-dependently enhances the
permeability of human primary endothelial cell mono-
layers independent of their anatomical origin, and (2)
co-operates with IL-1β, further enhancing IL-1β-induced
permeability of macro-and micro- vascular endothelial
monolayers.
Methods
Cell culture
Human coronary artery endothelial cells (HCAEC), hu-
man pulmonary artery endothelial cells (HPAEC), hu-
man cardiac microvascular endothelial cells (HCMVEC),
human dermal microvascular endothelial cells
(HDMVEC, all from Clonetics, Lonza), and human brain
microvascular endothelial cells (HBMVEC, Cell Systems)
were propagated as described (Skaria et al., 2017a) and
treated with recombinant human RSPO3 (doses ranging
from 250 to 1000 ng/mL, PeproTech) and recombinant
human IL-1β (20 U/mL, PeproTech) as given in the sup-
plementary methods (Additional file 1: Supplementary
methods ). For details on endothelial cell
characterization, see supplementary methods.
Immunoblotting
Immunoblotting of RSPO3 and quantification of band
densities were carried out as described (Skaria et al.,
2017b), and given in the supplementary methods
(Additional file 1). The following primary antibody was
used with dilution indicated: rabbit anti-RSPO3, poly-
clonal (1:500, Abcam). Anti-rabbit IgG-HRP-linked
whole antibody, from donkey (1:5000, GE Healthcare
UK Limited) was used as the secondary antibody.
Live recording of endothelial monolayer barrier function
using ECIS
The response of endothelial monolayer barrier to a par-
ticular stimulus can be assessed in real-time in a fully
standardized manner by continuously recording changes
in trans-endothelial electrical resistance (TEER) using
ECIS (Bernas et al., 2010). Endothelial barrier function
was continuously recorded using the 8W10E+ electrode
chamber arrays and ECIS Z-Theta system (Applied
Biophysics) with associated software v.1.2.126 PC, as de-
scribed (Skaria et al., 2017a) and given in the supple-
mentary methods (Additional file 1: Supplementary
methods).
Immunofluorescence staining
Immunofluorescence staining of β-catenin and
VE-cadherin were performed as described (Skaria et al.,
2016) and given in the supplementary methods (Add-
itional file 1). Quantitative assessment of gap index and
gap size index were carried out as described (Fraccaroli
et al., 2015) and given in the supplementary methods
(Additional file 1: Supplementary methods).
Statistical analysis
Data were analyzed using GraphPad Prism software ver-
sion 5.04 (GraphPad Software, San Diego, CA). An un-
paired 2-tailed Student’s t-test or, for comparing data
among groups, ANOVA followed by Bonferroni post
hoc test was used and differences were considered statis-
tically significant at p < 0.05.
Results and discussion
RSPO3 enhances the permeability of vascular endothelial
monolayers
To functionally test the effect of RSPO3 on monolayer
permeability, human primary macro- (HCAEC, HPAEC)
and micro- (HCMVEC, HBMVEC, HDMVEC) vascular
endothelial cells grown to tight monolayers in 8W10E+
array slides (Additional file 2: Figure S1A, B) were
treated with RSPO3 as indicated (Additional file 1: sup-
plementary methods, Additional file 3: Figure S2) and
changes in TEER of the endothelial monolayers were
continuously recorded for 12 h. As indicated by the sig-
nificant decrease in TEER, RSPO3 treatment
dose-dependently (Additional file 3: Figure S2) and at an
optimal dose of 500 ng/mL enhanced the permeability in
all endothelial monolayers tested independent of the
anatomical type. RSPO3-induced alterations in TEER be-
came significantly evident 2 h after beginning of treat-
ment and persisted for more than 6 h (Fig. 1,
Additional file 4: Figure S3). Since endothelial hyperper-
meability occurs due to increased actin cytoskeleton
polymerization and, in consequence gap formation
caused by β-catenin and VE-cadherin disruption at
inter-endothelial junctions (Vandenbroucke et al., 2008;
Weis, 2008), we next checked if RSPO3 alters the actin
cytoskeleton and generates inter-endothelial gaps. In
non-treated cells, thin actin filaments were scattered and
located at the cellular periphery as cortical actin
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(Additional file 5: Figure S4), and β-catenin
(Additional file 6: Figure S5) and VE-cadherin (Fig. 2)
were assembled at the cellular periphery forming tight
boarders between inter-cellular membranes. Treatment
with RSPO3 enhanced actin polymerization generating
notably thicker actin fibers (Additional file 5: Figure S4),
and disrupted β-catenin (Additional file 6: Figure S5)
and VE-cadherin at inter-cellular boarders, forming large
inter-endothelial gaps (Fig. 2a, b).
RSPO3 synergistically enhances the barrier destructive
effects of the pro-inflammatory mediator IL-1β
IL-1β secreted by activated leucocytes critically mediates
pro-inflammatory responses in acute and chronic
inflammatory diseases, cardiovascular diseases and
tumor inflammation (Dinarello, 2011). Because RSPO3
expression is induced by IL-1β in human leucocytes
(Williams et al., 2009) and vascular endothelium (Skaria
et al., 2017a) (Additional file 7: Figure S6), and can be
simultaneously present together with IL-1β during the
inflammatory response, we investigated the effect of
combined IL-1β/RSPO3 on vascular endothelial barrier
function. IL-1β treatment alone significantly increased
permeability in HCAEC, HPAEC, HBMVEC (Fig. 1), and
HDMVEC monolayers (Additional file 4: Figure S3).
Combined IL-1β/RSPO3 treatment synergistically in-
creased permeability in HCAEC, HPAEC, HCMVEC,
HBMVEC (Fig. 1) and HDMVEC monolayers
(See figure on previous page.)
Fig. 1 Automated real-time assessment of endothelial monolayer barrier function using the ECIS system. Uniform tight monolayers of HCAEC,
HPAEC, HCMVEC and HBMVEC cultured in stabilized and collagen coated 8W10E+ ECIS culture chambers were treated with RSPO3 (500 ng/mL),
IL-1β (20 U/mL) or a combination of RSPO3 and IL-1β. The line graphs are the original ECIS measurements obtained using ECIS Z Theta system
equipped with v.1.2.126 PC software and from one representative of three independent experiments run in duplicates at 4000 Hz (indicative of
cell-cell adhesion tightness). Bar graphs show the data of barrier function measurements continuously recorded for and at 12 h from three
independent experiments run in duplicates. Black, vehicle; Green, IL-1β; Yellow, RSPO3; Purple, RSPO3 + IL-1β. Error bars are mean ± S.D. ***P <
0.001 versus vehicle treatment, ****P < 0.001 versus RSPO3 and IL-1β single treatments
a
b
Fig. 2 Inter-cellular gaps in vascular endothelial monolayers treated with RSPO3 or IL-1β. a Immunofluorescence staining of VE-cadherin (red) and
DAPI staining of nuclei (blue) in HCAEC either untreated, or treated with RSPO3, IL-1β and combined IL-1β and RSPO3 for 6 h. Microphotographs
were taken using a Zeiss Axioskope equipped with Axio-CamMRm and AxioVision Rel.4.6 software and are representative of three independent
experiments run in triplicates. Original magnification, 630×. b Quantification of inter-endothelial gap index and gap size index in HCAEC treated
with RSPO3. Data are mean ± S.E.M of three independent experiments run in triplicates, *P < 0.05, ***P < 0.001 versus untreated (none)
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(Additional file 4: Figure S3). The synergistic effect of
RSPO3 with IL-1 was more pronounced in HCAEC,
HPAEC, HBMVEC (Fig. 1) and HDMVEC (Additional
file 4: Figure S3) monolayers compared to that observed
in HCMVEC (Fig. 1).
Although previous studies found that activated leu-
cocytes and vascular endothelial cells express high
levels of RSPO3 (Skaria et al., 2017a; Williams et al.,
2009), and its increased expression mediates patho-
genesis in intestinal inflammation (Kang et al., 2016)
and oncogenic pathways in cancers such as colon,
lung (Chartier et al., 2016; Marcucci et al., 2016;
Picco et al., 2017) and multiple myeloma (van Andel
et al., 2017), its function in the vascular system re-
mains still elusive. Most of the studies investigating
adult human vascular endothelial function in vitro
rely solely on cultured human umbilical vein endothe-
lial cells (HUVEC). It was later reported that HUVEC
obtained from the immune naïve fetal tissue shows
significant variations in function compared with adult
human vascular endothelium and hence may repre-
sent an inappropriate primary cell model of vascular
endothelium (Hwang et al., 2018; O'Donnell et al.,
2000; Tan et al., 2004). Therefore, to investigate the
effects of RSPO3 on adult human primary macro-
and micro- vascular endothelial monolayer barrier
function, we employed primary endothelial cells de-
rived from adult human coronary and pulmonary ar-
teries, and cardiac, brain, and dermal microvascular
beds, that were positively tested for vascular endothe-
lial markers and function, and are well established as
immunocompetent (Burton et al., 2011; Chandrasekar
et al., 2004; Franscini et al., 2004; Quinlan et al.,
1999; Skaria et al., 2017a; Skaria et al., 2016; Zeuke
et al., 2002). Here we show unequivocally that RSPO3
enhances permeability of adult human macro- and
micro- vascular endothelial monolayers. RSPO3, like
other secreted RSPO family members are Wnt signal-
ing enhancers functioning through Leu-rich
repeat-containing G protein-coupled receptors (LGR)
or syndecan-4 (SDC4) receptor to activate Wnt/β-ca-
tenin dependent or β-catenin independent Wnt/planar
cell polarity (PCP) signaling respectively (Chartier
et al., 2016; Knight & Hankenson, 2014; van Andel
et al., 2017). The whole genome microarray profiling
of 4 h and 8 h IL-1-activated human vascular endo-
thelium (accession GSE62281, NCBI GEO data reposi-
tory) in our previous study shows an upregulated
expression of SDC4 along with RSPO3 (Skaria et al.,
2017a). However, whether RSPO3-induced vascular
endothelial barrier dysfunction is mediated through
enhancement of constitutively expressed endothelial
barrier impairing Wnt5A (Skaria et al., 2017a), or any
other member of the Wnt family of 19 secreted
signaling proteins remains unclear. It is also not clear
whether a β-catenin dependent or independent Wnt
signaling is involved downstream of RSPO3 in human
vascular endothelium of different anatomical sites.
Endothelial barrier breakdown and in consequence,
monolayer hyperpermeability causes tissue edema
and contributes to morbidity and mortality associ-
ated with acute and chronic inflammatory diseases
(Chava et al., 2012; Weis, 2008). In cancer, endothe-
lial barrier dysfunction enhances angiogenesis and
metastasis by facilitating the intravasation of tumor
cells from the tumor into the blood vessel and
tumor cells’ extravasation out of the blood vessel to
the target tissues, respectively (Singleton, 2014;
Weis, 2008). Another major finding of this study is
the potency of RSPO3 to consistently enhance IL-1β
-mediated hyperpermeability in human macro- and
micro- vascular endothelial monolayers. It was
shown that IL-1β induces the expression of RSPO3
in human macrophages and vascular endothelium
(Skaria et al., 2017a; Williams et al., 2009). Pro-in-
flammatory responses mediated by IL-1 have critical
implications in an expanding number of local or systemic
acute and chronic inflammatory diseases such as sepsis,
severe systemic inflammatory syndromes, inflammatory
bowel disease and rheumatoid arthritis, and cancers such
as colon and myeloma. In these pathological states, in-
creased IL-1 expression strongly correlates with the dis-
ease progression and its neutralization leads to abrupt and
sustained decrease in disease severity (Dinarello, 2011). In
this context, the findings that RSPO3 is induced by
IL-1 and significantly enhances IL-1- mediated hyper-
permeability in both macro- (HCAEC, HPAEC) and two
(HBMVEC, HDMVEC) out of three micro- (HCMVEC,
HBMVEC, HDMVEC) vascular endothelial monolayers
tested are of prominent interest. The present study, there-
fore, stimulates further studies to delineate the endothelial
barrier impairing properties and mechanisms of RSPO3,
and its synergistic interaction with IL-1 in acute and
chronic inflammatory diseases and tumors.
Conclusion
Taken together, we show in this short report that
the matricellular protein RSPO3 is a novel perme-
ability factor inducing barrier dysfunction in human
primary vascular endothelial monolayers of macro-
and micro- vascular origin and RSPO3 acts synergis-
tic with the prototypic pro-inflammatory mediator
IL-1β. These findings expand the knowledge of the
role of RSPO3 in the human vascular system and
prompt further studies to investigate whether RSPO3
causes vascular leakage in IL-1-mediated inflamma-
tory diseases and cancers.
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Additional file 1: Supplementary methods. (PDF 124 kb)
Additional file 2: Figure S1. Confluent tight endothelial monolayer
formation in 8W10E+ ECIS arrays. Immediately after cell seeding,
resistance measurements (in Ohms) were started and are displayed as
normalized resistance (subsequent values were divided by initial values).
Increase in resistance with respect to time denotes that cells were
forming contacts between each other. The steady state shows the stage
at which maximum resistance is reached to form a tight monolayer.
Resistance measurements were carried out in duplicate wells which were
grouped and averaged to plot as single curve. Error bars represent mean
± S.E.M. Figures show the original plot of resistance measured at 4000 Hz
(indicative of cell-cell adhesion tightness). Red, blue: record of monolayer
formation of untreated (A) HCAEC and (B) HCMVEC grown in duplicate
wells from two independent experiments. All treatments for subsequent
assessment of barrier function were started after formation of stable tight
monolayers. (PDF 636 kb)
Additional file 3: Figure S2. Dose response assessment of RSPO3 on
endothelial barrier function using the ECIS system. Uniform tight
monolayers of HCAEC cultured in stabilized and collagen coated 8W10E+
ECIS array chambers were treated with 250 ng/mL, 500 ng/mL and
1000 ng/mL RSPO3. Data shown are the original resistance
measurements conducted at 4000 Hz (indicative of cell-cell adhesion
tightness) and are representative of three independent experiments.
Black, vehicle; Purple, RSPO3 (250 ng/mL); Yellow, RSPO3 (500 ng/mL);
Grey, RSPO3 (1000 ng/mL). (PDF 304 kb)
Additional file 4: Figure S3. Assessment of barrier function in dermal
microvascular endothelial monolayers. Uniform tight monolayers of
HDMVEC cultured in stabilized and collagen coated 8W10E+ array
chambers were treated with RSPO3, IL-1β or a combination of RSPO3
and IL-1β. (A) Original ECIS plot of resistance measurements (line graph)
from one representative of three independent experiments run in dupli-
cates at 4000 Hz (indicative of cell-cell adhesion tightness). (B) Bar graph
showing the data of barrier function measurements continuously re-
corded for and at 12 h from three independent experiments run in dupli-
cates. Black, vehicle; Green, IL-1β; Yellow, RSPO3; Purple, RSPO3 + IL-1β.
Error bars are mean ± S.D. ***P < 0.001 versus vehicle treatment, ****P <
0.001 versus RSPO3 and IL-1β single treatments. (PDF 242 kb)
Additional file 5: Figure S4. Actin cytoskeletal changes in vascular
endothelial monolayers treated with RSPO3 for 6 h. Green, phalloidin
staining of actin fibers; blue, DAPI staining of nuclei. Microphotographs
were taken using a Zeiss Axioskope equipped with Axio-CamMRm and
AxioVision Rel.4.6 software and are representative of three independent
experiments run in triplicates. Original magnification, 630×. (PDF 4093 kb)
Additional file 6: Figure S5. β-catenin alignment at adherens junctions
in vascular endothelial monolayers treated with RSPO3. Immunofluores-
cence staining of β-catenin (red) and DAPI staining of nuclei (blue) in
HCAEC either untreated, or treated with RSPO3 for 6 h. Microphotographs
were taken using a Zeiss Axioskope equipped with Axio-CamMRm and
AxioVision Rel.4.6 software and are representative of three independent
experiments run in triplicates. Original magnification, 630×. (PDF 5145 kb)
Additional file 7: Figure S6. Induction of RSPO3 expression by IL-1β in
human vascular endothelium. (A) Immunoblot of RSPO3 (31 kDa) in
HCAEC treated with IL-1β for 24 h. In-gel stained 75 kDa band served as
loading control and for immunoblot normalization in densitometric ana-
lysis. (B) RSPO3 expression levels quantified by densitometry analysis. Data
are mean ± S.E.M of three independent experiments, **P < 0.01 versus un-
treated (none). (PDF 191 kb)
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